Creative Medical Technology Holdings, Inc. (CELZ)
| Market Cap | 4.44M |
| Revenue (ttm) | 3,000 |
| Net Income (ttm) | -5.76M |
| Shares Out | 3.70M |
| EPS (ttm) | -2.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 516,946 |
| Open | 1.450 |
| Previous Close | 2.000 |
| Day's Range | 1.110 - 1.550 |
| 52-Week Range | 1.110 - 6.250 |
| Beta | 1.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About CELZ
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1... [Read more]
Financial Performance
In 2025, CELZ's revenue was $6,000, a decrease of -45.45% compared to the previous year's $11,000. Losses were -$6.00 million, 9.13% more than in 2024.
Financial StatementsNews
Creative Medical files to sell 3.05M shares of common stock
16:09 EDT Creative Medical (CELZ) files to sell 3.05M shares of common stock
Creative Medical expands ADAPT trial under new FDA clearance
Creative Medical (CELZ) announced that the FDA has cleared an expansion of the company’s FDA-cleared ADAPT clinical trial evaluating CELZ-201 for chronic lower back pain associated with degenerative d...
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
PHOENIX, June 22, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerativ...
Creative Medical launches national veteran data collection for Project PHOENIX
Creative Medical (CELZ) Technology announced the transition of Project PHOENIX, its proprietary veteran support registry and biodefense initiative, into its nationwide virtual data collection phase. D...
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics
Creative Medical knee data ‘highly positive,’ says Roth Capital
Roth Capital analyst Jonathan Aschoff says Creative Medical (CELZ) this morning announced “highly positive” results from its pilot study of Ultrasome, a cell-free regenerative therapy for osteoarthrit...
Creative Medical reports pilot study of Ultrasome meets priamry endpoint
Creative Medical (CELZ) announced results from its pilot study of Ultrasome, the company’s cell-free regenerative therapy for the treatment of osteoarthritis of the knee. The study achieved its primar...
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market
Creative Medical achieves second WHO INN milestone
Creative Medical (CELZ) Technology Holdings announced the achievement of its second International Nonproprietary Name milestone with the World Health Organization, marking continued regulatory progres...
Creative Medical announces interim data from ADAPT trial of CELZ-201
Creative Medical (CELZ) Technology Holding announced interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201, the Company’s proprietary perinatal tissue-derived ce...
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile
Creative Medical receives regulatory approval for BioDefense Burn Pit Initiative
Creative Medical (CELZ) Technology announced that its BioDefense Burn Pit Initiative has received regulatory approval to proceed, marking a significant milestone in the Company’s mission to address th...
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerativ...
Creative Medical completes enrollment in ADAPT trial for CELZ-201
Creative Medical (CELZ) Technology announced the completion of patient enrollment in its FDA-cleared ADAPT clinical trial evaluating CELZ-201, the Company’s proprietary perinatal tissue-derived cell t...
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain Completion of Enr...
Creative Medical announces WHO approval of olastrocel as INN for CELZ-201
Creative Medical (CELZ) Technology announced that the World Health Organization has approved “olastrocel” as the International Non-Proprietary Name for the active cellular substance in CELZ-201, the C...
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel's advancement across large unmet-need global markets Global assignment...
Creative Medical launches Biodefense Inc. Veterans Initiative
Creative Medical (CELZ) Technology Holdings announced the official launch of its BioDefense Inc. Veterans Initiative, a national program to combat the devastating long-term effects of toxic burn pit e...
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform
Creative Medical announces agreements for warrant exercise for $4.2M proceeds
Creative Medical (CELZ) Technology entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 ...
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, tod...
Creative Medical issues letter to shareholders
Creative Medical (CELZ) Technology issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer. “2025 has been a landmark year for Creative Medical. With the suppor...
Creative Medical Technology Holdings Issues Letter to Shareholders
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026 Ongoing Phase II Clinical Trials, Recently Issued Patents, and A...
Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs
Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical's Similar Research Focus Recent Issuance of ...
Creative Medical secures FDA Fast Track designation for CELZ-201-DDT
Creative Medical (CELZ) Technology announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of...